SWM
AMRX icon

SeaCrest Wealth Management’s Amneal Pharmaceuticals AMRX Stock Holding History

SeaCrest Wealth Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$4K – 579
2019
Q1 		$4K Hold
300
– – ﹤0.01% 1752
2018
Q4 		$4K Hold
300
– – ﹤0.01% 1731
2018
Q3 		$7K Hold
300
– – ﹤0.01% 1752
2018
Q2 		$5K Buy
+300
New +$5.26K ﹤0.01% 1799

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SeaCrest Wealth Management's AMRX Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2019, closing a stake of 300 shares — an estimated $4K sold.

SeaCrest Wealth Management first reported a position in AMRX in Q2 2018 and held it in 4 quarters. The position peaked at $7K in Q3 2018. 129 funds tracked by Wall St. Rank hold AMRX as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Amneal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 300 Amneal Pharmaceuticals shares in Q2 2019, an estimated $4K.
  • SeaCrest Wealth Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • SeaCrest Wealth Management's Amneal Pharmaceuticals position peaked at $7K in Q3 2018.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.